At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses ARAMIS, a multinational, randomised, double-blind, placebo-controlled, phase 3 trial that is evaluating the efficacy and safety study of ODM-201, a novel second-generation oral androgen receptor inhibitor, in men with high-risk non-metastatic castration-resistant prostate cancer.
ARAMIS trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer
26th August 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?